
#### **Objectives**

- Sources of data in epidemiology
- Understand methods of assessments of frequency of diseases
- Indicators


# Sources of Data in Epidemiology

#### **Birth and Death Certificates**





#### **Patient Record**



### Questionnaire

| A   | . About you and your teaching  |             |            |           |        |
|-----|--|-------------|------------|-----------|--------|
| 1   | . Your gender: Male   Female   |             |            |           |        |
| 2   | . Your teaching experience: <1   | year 1-     | 5 years =  | > 5 years |        |
|     | a) How long have you been teaching?  |             |            |           |        |
|     | b) How long have you been in your current post?  |             |            |           |        |
| 3   | . How much time do you spend in teaching and preparation   |             |            |           | > 10   |
|     | English Language at P7 in a typical week?  | hou         |            |           | hours  |
|     | a) Teaching  |             | _          |           |        |
|     | b) Preparation   |             |            |           |        |
| 4   | . On professional development:   |             |            | Yes       | No     |
|     | <ul> <li>a) Have you had any professional development in English</li> </ul>  | Language    | in the las | st 🗆      |        |
|     | two years?  b) Are you satisfied with the number of professional deve  | lopment     |            |           |        |
|     | opportunities available to you in English Language?  |             |            | _         |        |
| 5   | . Please indicate your opinion about your pupils' motivation   | n to        | Very       |           | Very   |
|     | learn, behaviour and lesson attendance (in general):   |             | good (     | Good Poor | poor   |
|     | a) Motivation to learn   |             |            |           |        |
|     | b) Behaviour in class  |             |            |           |        |
|     | c) Lesson attendance   |             |            |           |        |
| 6   | . Please indicate how you use 5-14 National Assessments  | with your   |            |           |        |
|     | P7 pupils: a) With individual pupils when you judge they have attained.  |             | Always     | Sometimes | Never  |
|     |  |             |            | H         |        |
|     | <ul> <li>b) With groups of pupils when you judge they have attained</li> <li>c) With the whole class, when you judge most have attained</li> </ul> |             |            | H         |        |
|     | irrespective of time of year   | eu a ievei, |            |           |        |
|     | d) With the whole class at set times each year   |             |            |           |        |
| 1 7 | . If you use National Assessments with your P7 pupils, for   |             |            |           |        |
|     | what proportion of pupils would you say the test results   | Fewer       | Over       | The       | Almost |
|     | and your own judgments coincide?   | than half   | half       | majority  | all    |
|     | a) Reading   | _           | _          |           |        |
|     | b) Writing   |             |            |           |        |
|     |  |             |            |           |        |

## Laboratory Results

#### **Laboratory Results**

Four AIDS patients with compromised immune function

|             |       |     |          | Time     | on LifeOne | feOne    |        |  |  |  |  |
|-------------|-------|-----|----------|----------|------------|----------|--------|--|--|--|--|
| Name        | Age   | Sex | Start    | Test #1  | (Days)     | Test #2  | (Days) |  |  |  |  |
| Aispuro, F  | 24    | M   | 09/28/02 | 11/09/02 | 42         | 01/06/03 | 100    |  |  |  |  |
| Balcazar, M | 26    | M   | 10/03/02 | 11/08/02 | 36         | 01/09/03 | 98     |  |  |  |  |
| Cano, D*    | 48    | M   | 10/14/02 | 12/02/02 | 49         | 01/06/03 | 84     |  |  |  |  |
| Jimenez, R  | 35    | M   | 10/15/02 | 11/07/02 | 23         | 01/07/03 | 84     |  |  |  |  |
| Average     | 33.25 |     |          |          | 38         |          | 92     |  |  |  |  |

|             | 202   | solute Lymp<br>inge: 1,000 - | •       | 0.1    | R     | T-cells<br>ange: 740 - 2 |         | ı [    | CD4 (CD3+CD4+)<br>Range: 440 - 1,600 cells/ml |         |         |        |
|-------------|-------|------------------------------|---------|--------|-------|--------------------------|---------|--------|---|---------|---------|--------|
| Name        | Begin | Test #1                      | Test #2 | Change | Begin | Test #1                  | Test #2 | Change | Begin   | Test #1 | Test #2 | Change |
| Aispuro, F  | 1,500 | 2,600                        | 2,900   | 1,400  | 975   | 1,850                    | 1,925   | 950    | 148   | 335     | 389     | 241    |
| Balcazar, M | 1,900 | 1,500                        | 1,680   | -220   | 1,300 | 1,100                    | 1,200   | -100   | 150   | 225     | 350     | 200    |
| Cano, D*    | 1,200 | 1,500                        | 1,400   | 200    | 840   | 626                      | 1,050   | 210    | 117   | 575     | 156     | 39     |
| Jimenez, R  | 1,300 | 2,500                        | 1,700   | 400    | 885   | 1,750                    | 1,200   | 315    | 151   | 385     | 345     | 194    |
| Average     | 1,475 | 2,025                        | 1,920   | 445    | 1,000 | 1,332                    | 1,344   | 344    | 142   | 380     | 310     | 169    |
|             |       | IMPE                         | OVEDRY  | 30.2%  |       | IMPR                     | OVED RY | 34 4%  |   | IMPR    | OVEDRY  | 119 1% |

|             | Refere | ls/ml   | Refer   | CD4/ence Range: |       | s/ml    | HIV-1 (RNA) Viral Load<br>Reference Range: No detected copies/ml |        |        |         |         |         |
|-------------|--------|---------|---------|-----------------|-------|---------|--|--------|--------|---------|---------|---------|
| Name        | Begin  | Test #1 | Test #2 | Change          | Begin | Test #1 | Test #2  | Change | Begin  | Test #1 | Test #2 | Change  |
| Aispuro, F  | 235    | 450     | 476     | 241             | 0.6   | 0.8     | 0.9  | 0.3    | 1,900  | 1,900   | 2,100   | 200     |
| Balcazar, M | 150    | 326     | 420     | 270             | 1.0   | 0.7     | 0.7  | -0.3   | 67,400 | 4,010   | 2,500   | -64,900 |
| Cano, D*    | 168    | 189     | 189     | 21              | 0.7   | 3.0     | 1.0  | 0.3    | 2,900  | 75      | 250     | -2,650  |
| Jimenez, R  | 222    | 525     | 392     | 170             | 0.7   | 0.8     | 0.9  | 0.2    | 16,000 | 2,100   | 2,010   | -13,990 |
| Average     | 194    | 373     | 369     | 176             | 0.8   | 1.3     | 0.9  | 0.1    | 22,050 | 2,021   | 1,715   | -20,335 |
|             |        | IMPR    | OVEDRY  | 90.6%           |       | IMPR    | OVED RY  | 15 6%  |        | IMPR    | OVED RY | 92 2%   |

|             |       | Gluc<br>mg/ |         |        |       | Choles<br>mg/ |         | ſ      | Triglicerides<br>mg/dl |         |         |        |
|-------------|-------|-------------|---------|--------|-------|---------------|---------|--------|------------------------|---------|---------|--------|
| Name        | Begin | Test #1     | Test #2 | Change | Begin | Test #1       | Test #2 | Change | Begin                  | Test #1 | Test #2 | Change |
| Aispuro, F  | 86    | 82          | 98      | 12     | 174   | 176           | 170     | -4     | 282                    | 150     | 144     | -138   |
| Balcazar, M | 95    | 85          | 78      | -17    | 219   | 195           | 185     | -34    | 199                    | 138     | 140     | -59    |
| Cano, D*    | 149   | 107         | 105     | -44    | 264   | 268           | 269     | 5      | 327                    | 540     | 730     | 403    |
| Jimenez, R  | 107   | 88          | 97      | -10    | 268   | 164           | 177     | -91    | 540                    | 339     | 344     | -196   |
| Average     | 109   | 91          | 95      | -15    | 231   | 201           | 200     | -31    | 337                    | 292     | 340     | 3      |
|             | 1     | IMPR        | OVED BY | 13.5%  |       | IMPR          | OVED BY | 13.4%  |                        | RED     | UCED BY | 0.7%   |

\*Patient Cano,D. stopped taking the formula after 23 days due to a misunderstanding of the protocol. His follow up lab work was done on day 38, and began taking the formula again.









# DATA collection SHOULD be taken seriously

# You SHOULD KNOW What and Why you are collecting





Population











# RATIO

## Indicator






# All calculations are used as Indicators

1- **Simplify** information about complex phenomena in order to **improve communication** 






#### 2- Monitor progress over time



3- **Indicate** (POINTS) that something is good or wrong is going on, this depends on the indicator threshold





#### **Indicator Threshold**

Definition of indicator thresholds and (or) targets applies to the individual measures under each indicator.

The threshold is indicated in the indicator description statement.

A threshold is **setting certain norms and criteria**.

Any health programme, department, or institution, strives to reach the indicator threshold.

#### **Example**

The minimum threshold for the immunization coverage of the compulsory vaccination schedule in country X is 98%.

Immunization Coverage – Number of newborns in 2023 eligible for vaccination

Total number of newborns in 2023

4- An indicator must be useful to its intended audience. It must convey information that is meaningful to decision makers and in a form which is easily understood





# Public and Decision Makers are interested in an answer to the question of

# What are the risks? OR What is the probability that the event would occur or happen

# **Epidemiology is** DATA driven

#### WHAT IS QUALITY DATA

## ACCURACY

- Data should be accurate for the intended use
- Variables should have consistent well communicated definitions

### VALIDITY

-Data should measure what is intended to be measured

### RELIABILITY

 Data should reflect stable and consistent data collection methods

#### TIMELINESS

Data should be captured as quickly as possible
 after the event or activity and must be available for the
 intended use within a reasonable time period

 Data must be available quickly and frequently enough to support information needs and to influence decisions

## RELEVANCE

 Data should be relevant to the question for which it is addresses

#### COMPLETENESS

Data should be checked for outliers and missing data

#### ALIGNMENT

Alignment with other data sources should be identified,
 validated, and checked for accuracy between variables

## OWNERSHIP

 A specific organization, agency, or individual should be identified as having primary ownership of the data